Outcomes with drug-coated balloons in small-vessel coronary artery disease

被引：21

作者：

Megaly, Michael ^{[1
,2
,3
]}

Rofael, Michael ^{[4
]}

Saad, Marwan ^{[5
]}

Rezq, Ahmed ^{[6
]}

Kohl, Louis P. ^{[3
]}

Kalra, Ankur ^{[7
]}

Shishehbor, Mehdi ^{[7
]}

Soukas, Peter ^{[8
]}

Abbott, J. D. ^{[8
]}

Brilakis, Emmanouil S. ^{[1
,2
]}

机构：

[1] Abbott NW Hosp, Minneapolis Heart Inst, 920 E 28th St 300, Minneapolis, MN 55407 USA

[2] Minneapolis Heart Inst Fdn, Minneapolis, MN USA

[3] Hennepin HealthCare, Div Cardiovasc Med, Minneapolis, MN USA

[4] Univ South Carolina, Palmetto Hlth Columbia, Div Cardiovasc Med, Columbia, SC 29208 USA

[5] Univ Arkansas, Dept Med, Div Cardiovasc Med, Little Rock, AR 72204 USA

[6] Ain Shams Univ, Dept Cardiovasc Med, Cairo, Egypt

[7] Case Western Reserve Univ, Sch Med, Dept Med, Div Cardiovasc Med, Cleveland, OH 44106 USA

[8] Brown Univ, Dept Med, Warren Alpert Med Sch, Div Cardiovasc Med, Providence, RI 02912 USA

来源：

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS | 2019年 / 93卷 / 05期

关键词：

drug-coated balloons; drug-eluting balloons; small-vessel disease coronary disease; IN-STENT RESTENOSIS; BARE-METAL STENT; EVEROLIMUS-ELUTING STENTS; DE-NOVO LESIONS; CLINICAL-OUTCOMES; FOLLOW-UP; PACLITAXEL; METAANALYSIS; ANGIOPLASTY; MULTICENTER;

D O I：

10.1002/ccd.27996

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundPercutaneous coronary intervention (PCI) of small-vessel coronary artery disease (SVD) is associated with increased risk of restenosis. The use of drug-coated balloons (DCBs) in SVD has received limited study. ObjectivesTo assess the outcomes of DCB in the treatment of SVD compared with the standard of care. MethodsWe performed a meta-analysis of all studies published between January 2000 and September 2018 reporting the outcomes of DCB versus other modalities in the treatment of de novo SVD. ResultsSeven studies with 1,824 patients (1,938 lesions) were included (four randomized controlled trials and three observational studies). During a mean follow-up of 14.510 months, DCBs were associated with a similar risk of target lesion revascularization (TLR) (OR: 0.99, 95% CI: 0.54, 1.84, P=97) and major adverse cardiovascular events (MACE) (OR: 0.86, 95% CI: 0.51, 1.45, P=0.57) compared with drug-eluting stents (DES). During a mean follow-up of 7 +/- 1.5 months, DCBs were associated with a significantly lower risk of TLR (OR: 0.19, 95% CI 0.04-0.88, P=0.03) and binary restenosis (OR: 0.17, 95% CI 0.08-0.37, P=<0.00001) compared with noncoated balloon angioplasty. ConclusionThe use of DCBs in SVD is associated with comparable outcomes when compared with DES and favorable outcomes when compared with balloon angioplasty.

引用

页码：E277 / E286

页数：10

共 56 条

[1] Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials [J].